


The WHO Council on the Economics of Health for All





Mariana Mazzucato

Professor of the Economics of Innovation and Public Value and Founding Director in the Institute for Innovation and Public Purpose at University College London.

Professor Senait Fisseha

Chief Adviser to the Director General, WHO



Professor Stephanie Kelton

Professor of Economics and Public Stony Brook University



Zélia Maria Profeta da Luz >

Director of the Instituto Ren Rachou-Fiocruz Minas. Oswaldo Cruz Foundation



Dr Vera Songwe >

Under-Secretary-General. United Nations and Executive Secretary of the Economic Commission for Africa



Professor Jayati Ghosh >

Professor of Economics, University of Massachusetts at Amherst, USA



Professor Ilona Kickbusch >

Founding Director and Chair, Global Health Centre, Graduate Institute of International and Development Studies in Geneva



Kate Raworth >

Professor of Practice. Amsterdam University of Applied



Dame Marilyn Waring >



Vanessa Huang >

General Partner,





Professor of Public Policy. Auckland University of Technology



The Council on the Economics of Health for All brings together different areas of policy, which can no longer be seen separately from health: social policy, economic policy, and innovation policy.

Its mission is to bring **health and wellbeing to the centre** of how we think about **purpose**, **value** and **development**. It provides a new approach to shape the economy with the objective of building healthy societies that are just, inclusive, equitable and sustainable."


4 pillars for re-thinking the Economics of Health for All












»Redesigning the health innovation ecosystem for the common good requires a major shift from a model where innovation is seen as being driven by market forces, to a model that is collectively governed in the public interest.«



THE LANCET

Regional R&D hubs, adapting versatile technology platforms,

eg mRNA technology

Vision and values of the new framework for effective health innovation

- Health technologies for PPR should be considered common goods, not private commodities
- A new business model is needed to deliver common goods for PPR
- Collective intelligence and technology sharing are the most effective ways to deliver innovation for public health
- A true end-to-end approach to medical innovation is rooted in equity at every step
- Appropriate health technologies are those that ensure the right outcome for health
- Structuring partnerships with the private sector towards shared public health goals

COMMENT | VOLUME 401, ISSUE 10374, P324-328, FEBRUARY 04, 2023 Stopping epidemics when and where they occur Els Torreele 🖾 • Michel Kazatchkine • Joanne Liu • Mark Dybul • Mauricio Cárdenas • Sudhvir Singh • Helena Legido Quigley • Christine McNab • Ellen Johnson Sirleaf • Mariana Mazzucato • Helen Clark • Published: January 12, 2023 • DOI: https://doi.org/10.1016/S0140-6736(23)00015-6 • (A) Check for upon

Current vaccine market: unbalanced, segmented, inequitable

(with 20 years of "market fixing" for LMICs)

Figure 9: Top 10 manufacturers by value (excluding COVID-19), 2021

Figure 11: Top 10 manufacturers
by volume (excluding COVID-19), 2021



"We need to strike a much better balance between serving national interests, global public health objectives and commercial incentives.

The only means to achieve this is through high-level diplomacy between countries and commitment to a new paradigm"

From fixing LMIC market failures to shaping a global health-industrial ecosystem for the common good

- HIC vaccine market: government interventions to create and maintain a "profitable business case" for private companies
 - Long term investments in R&D and domestic production (grants, subsidies, IP and regulatory incentives)
 - Willingness to pay premium prices for vaccines; public health vaccination programs
 - For health security (e.g BARDA) additional market push & pull mechanisms cfr mpox
- LMIC-market: donor-driven market fixing approach to create a "minimally viable market" for DCVMs to secure vaccine manufacturing at the lowest possible price
 - Assumes the overall (mainly HIC) market operates fine as is; equity can be solved by market fixing in the margins (ex-post: charity, market segmentation)
 - Does not address the structural inequities and dependencies (cfr Covid-19)
- Health equity needs transformational change: shaping the health-industrial ecosystem for the common good
 - Goal is improving people's health / health security, not fixing markets or creating profitable businesses

The mRNA Hub as a pilot for transformative change?

WHO Economics Council recommendation:

- Consider mRNA Hub as a common good for epidemic preparedness, driven by South-South collaboration and pursuing health security with equity and resilience at its heart
- Co-create a long-term collaborative, collectively governed platform for mRNA-technology based R&D and manufacturing for the common good, to serve public health goals and equity
- Sustainability: end-to-end value proposition for common good

Value proposition:

access when and where needed into a regenerative business model for health

Investment in the development A common good approach of an mRNA technology to health innovation builds on platform and its sharing among whole-of-government collaborating partners, will leadership and dedicated increase the LMIC capacity for **Shared mRNA** policies towards the shared collaborative innovation and technology platform goal of Health for All and manufacturing in response to greater health security and local health needs when and resilience against epidemic where needed. outbreaks. Common good approach The versatility of the mRNA technology platform is wellsuited to adapt to different An end-to-end approach **Needs-driven** disease targets, using links investments in the mRNA collective intelligence and R&D portfolio platform, technology sharing building a portfolio of R&D and a portfolio of R&D projects addressing local projects to clinical needs, and that can be assessment, manufacturing, **End to End** evaluated in public healthavailability, and equitable

focused clinical trial networks.

Conducive policy environment: recommendations

Valuing what matters

- Consider countermeasures and other critical health technologies as common goods, not market commodities
- Value establishment of distributed technological capacity for health R&D and manufacturing as strategic asset for health security and equity
- Foster regenerative and health purpose-driven rather than profit-generating business models

Shaping innovation policy for health equity

- Ensure technology sharing with freedom to operate around critical technology platforms, and govern as common good
- Incentivize, prioritize and finance portfolio approach of needs-driven R&D for maximal health impact
- Promote open science, collective intelligence, sharing over secretive competition (IP reform as needed)

Finance for the common good

- Increase access to affordable capital to invest in health and health resilience as common good, including through reform of the global finance architecture (cfr Bridgetown 2022)
- Ensure pandemic funding streams support end-toend value proposition for R&D and manufacturing of countermeasures for common good

Building (state) capacity

- Invest in skilled workforce, and create conditions to retain them for public health purpose
- Use finance, procurement, industrial policy etc as tools to shape ecosystem for needs-driven R&D and manufacturing for health, not profit
- Foster whole-of-government approach, and South-South collaboration around this collective effort



Acknowledgements:

WHO Economics Council:

- Mariana Mazzucato, Chair
- Co-authors/researchers: Alberto Huitron, Devika Dutt
- Ritu Sadana, Head of the Secretariat

Interviewees and informants:

- WHO/MPP: Martin Nicholson, Claudia Nannei, Christopher Chadwick,
 Charles Gore, Marie-Paule Kieny, Martin Friede, Soumya Swaminathan
- Petro Terblanche, Afrigen, South Africa
- Analia Acabal, German Sanchez, Fernando Lobos, Sinergium Biotech, Argentina
- Inna Deniak and Maksym Vorokhobin, Darnitsa, Ukraine
- Patrick Tippo, BioVac, South Africa
- Mina Adel, BioGeneric Pharma SAE, Egypt
- Abdul Muktadir and Mainul Ahasan, Incepta Vaccines, Bangladesh
- Neni Nurainy and Adriansjah Azhari, Biofarma, Indonesia
- Arthur Salaaun, Boston Consulting Group
- Debbie King, Wellcome Trust
- Frederick Abbott, Florida State University College of Law
- Fatima Hassan, Health Justice Initiative
- Brook Baker, Northeastern University School of Law

Thank You!

